Octreotide vs Semaglutide
Updated September 27, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Octreotide and Semaglutide (also searched as Semaglutide vs Octreotide) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Octreotide centers on neuro, while Semaglutide leans toward metabolic. On indexed research, Semaglutide is ahead (Octreotide: 33 studies, Human evidence; Semaglutide: 57, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Octreotide is strongest for neuro; Semaglutide for metabolic.
- •Evidence: Octreotide Human evidence (33 studies) vs Semaglutide Human clinical (57).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
Somatostatin analog | Treats acromegaly and tumors
GLP-1 Agonist | Type 2 Diabetes and Obesity Management
Octreotide vs Semaglutide: side-by-side
| Metric | Octreotide | Semaglutide |
|---|---|---|
| Class | Neuro | Metabolic |
| Regulatory status | Research use only | FDA-approved |
| Evidence grade | Human evidence | Human clinical |
| Studies indexed | 33 | 57 |
| Research level | Extensively Studied | FDA Approved |
| Strongest effect | Neuro & mood | Metabolic & appetite |
| Healing & recovery | 3.0▲ | 1.0 |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 2.0 | 5.0▲ |
| Neuro & mood | 4.0▲ | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 1.0▲ | 1.0▲ |
| Skin & aesthetics | 0.0 | 4.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Octreotide | Semaglutide |
|---|---|---|
| Mechanism | SSTR2 and SSTR5 receptor agonist | GLP-1 receptor agonist |
| Route | Subcutaneous injection | Subcutaneous injection (oral form also available) |
| Half-life | ~2 hours | ~7 days (≈165 h) |
| Time to peak | 30 min | 1–3 days |
| Duration of action | ~12 hours | Weekly dosing |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Octreotide?
Research peptide discovered via AI researcher. peptide-based therapeutic
Full Octreotide profile, mechanism & studies →What is Semaglutide?
Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a hormone involved in glucose metabolism and appetite regulation. As a GLP-1 receptor agonist, semaglutide enhances insulin secretion in response to elevated blood glucose levels, suppresses glucagon secretion, and slows gastric emptying, leading to improved glycemic control. Additionally, it promotes satiety, contributing to weight loss, which has made it a focus of research for managing both type 2 diabetes and obesity.
Full Semaglutide profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Octreotide | 3.0/5 effect signal |
| Metabolic | Semaglutide | 5.0/5 effect signal |
| Neuro | Octreotide | 4.0/5 effect signal |
| Inflammation | Even | Both ~1.0/5 |
| Skin | Semaglutide | 4.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Octreotide and Semaglutide?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Octreotide vs Semaglutide: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Octreotide has 33 approved studies indexed (Human evidence), and Semaglutide has 57 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Octreotide or Semaglutide better?
It depends on your goal. Octreotide is strongest for neuro; Semaglutide for metabolic. Semaglutide has more indexed studies (57). See the goal-by-goal breakdown above.
Is Octreotide or Semaglutide better for weight loss?
Semaglutide shows the stronger metabolic & appetite profile (5.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Which has more research, Octreotide or Semaglutide?
Octreotide has 33 approved studies indexed (Human evidence); Semaglutide has 57 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack Octreotide and Semaglutide?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Octreotide vs Semaglutide?
Octreotide: no community-reported effects logged yet. Semaglutide: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Octreotide or Semaglutide FDA-approved?
Octreotide is a research-use compound and is not FDA-approved. Semaglutide is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Semaglutide better than Octreotide?
For metabolic, Semaglutide has the edge; for neuro, Octreotide does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed September 27, 2026.